Literature DB >> 22096244

P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment.

Abdel Kareem Azab1, Phong Quang, Feda Azab, Costas Pitsillides, Brian Thompson, Triona Chonghaile, John T Patton, Patricia Maiso, Val Monrose, Antonio Sacco, Hai T Ngo, Ludmila M Flores, Charles P Lin, John L Magnani, Andrew L Kung, Anthony Letai, Ruben Carrasco, Aldo M Roccaro, Irene M Ghobrial.   

Abstract

Interactions between multiple myeloma (MM) cells and the BM microenvironment play a critical role in the pathogenesis of MM and in the development of drug resistance by MM cells. Selectins are involved in extravasation and homing of leukocytes to target organs. In the present study, we focused on adhesion dynamics that involve P-selectin glycoprotein ligand-1 (PSGL-1) on MM cells and its interaction with selectins in the BM microenvironment. We show that PSGL-1 is highly expressed on MM cells and regulates the adhesion and homing of MM cells to cells in the BM microenvironment in vitro and in vivo. This interaction involves both endothelial cells and BM stromal cells. Using loss-of-function studies and the small-molecule pan-selectin inhibitor GMI-1070, we show that PSGL-1 regulates the activation of integrins and downstream signaling. We also document that this interaction regulates MM-cell proliferation in coculture with BM microenvironmental cells and the development of drug resistance. Furthermore, inhibiting this interaction with GMI-1070 enhances the sensitization of MM cells to bortezomib in vitro and in vivo. These data highlight the critical contribution of PSGL-1 to the regulation of growth, dissemination, and drug resistance in MM in the context of the BM microenvironment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22096244      PMCID: PMC3286211          DOI: 10.1182/blood-2011-07-368050

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  37 in total

1.  Synthesis and biological evaluation of a potent E-selectin antagonist.

Authors:  G Thoma; W Kinzy; C Bruns; J T Patton; J L Magnani; R Bänteli
Journal:  J Med Chem       Date:  1999-11-18       Impact factor: 7.446

2.  Synthesis and biological evaluation of a sialyl Lewis X mimic with significantly improved E-selectin inhibition.

Authors:  G Thoma; J L Magnani; J T Patton
Journal:  Bioorg Med Chem Lett       Date:  2001-04-09       Impact factor: 2.823

3.  Design and synthesis of sialyl Lewis x mimics as E-selectin inhibitors.

Authors:  N Kaila; B E Thomas; P Thakker; J C Alvarez; R T Camphausen; D Crommie
Journal:  Bioorg Med Chem Lett       Date:  2001-01-22       Impact factor: 2.823

4.  Nanomolar E-selectin inhibitors: 700-fold potentiation of affinity by multivalent ligand presentation.

Authors:  G Thoma; R O Duthaler; J L Magnani; J T Patton
Journal:  J Am Chem Soc       Date:  2001-10-17       Impact factor: 15.419

Review 5.  Design and synthesis of sialyl Lewis(x) mimics as E- and P-selectin inhibitors.

Authors:  Neelu Kaila; Bert E Thomas
Journal:  Med Res Rev       Date:  2002-11       Impact factor: 12.944

6.  The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma.

Authors:  Teru Hideshima; Dharminder Chauhan; Toshiaki Hayashi; Klaus Podar; Masaharu Akiyama; Deepak Gupta; Paul Richardson; Nikhil Munshi; Kenneth C Anderson
Journal:  Mol Cancer Ther       Date:  2002-05       Impact factor: 6.261

7.  P-selectin glycoprotein ligand-1-deficient mice have impaired leukocyte tethering to E-selectin under flow.

Authors:  Lijun Xia; Markus Sperandio; Tadayuki Yago; J Michael McDaniel; Richard D Cummings; Sonia Pearson-White; Klaus Ley; Rodger P McEver
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

8.  Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis.

Authors:  Lubor Borsig; Richard Wong; Richard O Hynes; Nissi M Varki; Ajit Varki
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-19       Impact factor: 11.205

9.  Tyrosine sulfation of the amino terminus of PSGL-1 is critical for enterovirus 71 infection.

Authors:  Yorihiro Nishimura; Takaji Wakita; Hiroyuki Shimizu
Journal:  PLoS Pathog       Date:  2010-11-04       Impact factor: 6.823

10.  P-selectin glycoprotein ligand-1 mediates L-selectin-dependent leukocyte rolling in venules.

Authors:  Markus Sperandio; Michael L Smith; S Bradley Forlow; Timothy S Olson; Lijun Xia; Rodger P McEver; Klaus Ley
Journal:  J Exp Med       Date:  2003-05-19       Impact factor: 14.307

View more
  55 in total

1.  Myeloma as a model for the process of metastasis: implications for therapy.

Authors:  Irene M Ghobrial
Journal:  Blood       Date:  2012-04-24       Impact factor: 22.113

2.  In vivo adhesion of malignant B cells to bone marrow microvasculature is regulated by α4β1 cytoplasmic-binding proteins.

Authors:  M Martínez-Moreno; M Leiva; N Aguilera-Montilla; S Sevilla-Movilla; S Isern de Val; N Arellano-Sánchez; N C Gutiérrez; R Maldonado; J Martínez-López; I Buño; J A García-Marco; P Sánchez-Mateos; A Hidalgo; A García-Pardo; J Teixidó
Journal:  Leukemia       Date:  2015-12-10       Impact factor: 11.528

3.  Ezrin-radixin-moesin-binding sequence of PSGL-1 glycoprotein regulates leukocyte rolling on selectins and activation of extracellular signal-regulated kinases.

Authors:  Caroline Spertini; Bénédicte Baïsse; Olivier Spertini
Journal:  J Biol Chem       Date:  2012-02-06       Impact factor: 5.157

Review 4.  The Platelet Lifeline to Cancer: Challenges and Opportunities.

Authors:  Monika Haemmerle; Rebecca L Stone; David G Menter; Vahid Afshar-Kharghan; Anil K Sood
Journal:  Cancer Cell       Date:  2018-04-12       Impact factor: 31.743

5.  The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma.

Authors:  Siobhan V Glavey; Salomon Manier; Alessandro Natoni; Antonio Sacco; Michele Moschetta; Michaela R Reagan; Laura S Murillo; Ilyas Sahin; Ping Wu; Yuji Mishima; Yu Zhang; Wenjing Zhang; Yong Zhang; Gareth Morgan; Lokesh Joshi; Aldo M Roccaro; Irene M Ghobrial; Michael E O'Dwyer
Journal:  Blood       Date:  2014-07-24       Impact factor: 22.113

6.  3D tissue-engineered bone marrow: what does this mean for the treatment of multiple myeloma?

Authors:  Pilar de la Puente; Abdel Kareem Azab
Journal:  Future Oncol       Date:  2016-03-30       Impact factor: 3.404

Review 7.  Eviction from the sanctuary: Development of targeted therapy against cell adhesion molecules in acute lymphoblastic leukemia.

Authors:  Sonali P Barwe; Anthony Quagliano; Anilkumar Gopalakrishnapillai
Journal:  Semin Oncol       Date:  2017-07-11       Impact factor: 4.929

Review 8.  Extramedullary multiple myeloma.

Authors:  Manisha Bhutani; David M Foureau; Shebli Atrash; Peter M Voorhees; Saad Z Usmani
Journal:  Leukemia       Date:  2019-11-27       Impact factor: 11.528

9.  Clinical relevance of PET/CT in patients with newly diagnosed multiple myeloma.

Authors:  Chaoyu Wang; Ling Wu; Chengtao Sun; Yizhuo Zhang
Journal:  Int J Clin Exp Pathol       Date:  2019-02-01

10.  Reflection on the discovery of carcinoembryonic antigen, prostate-specific antigen, and cancer antigens CA125 and CA19-9.

Authors:  Eleftherios P Diamandis; Robert C Bast; Phil Gold; T Ming Chu; John L Magnani
Journal:  Clin Chem       Date:  2012-11-30       Impact factor: 8.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.